For India’s pharmaceutical industry, the latest US tariff decision brings relief — but not across the entire medicines sector. Washington has given zero-tariff treatment to certain specialty medicines and their associated ingredients from India and 19 other jurisdictions, even as the US moves ahead with a 100 per cent tariff on specified patented pharmaceutical products..
